Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
作者： K. Margolin , M. S. Gordon , E. Holmgren , J. Gaudreault , W. Novotny
DOI: 10.1200/JCO.2001.19.3.851
关键词:
摘要: PURPOSE: Tumor angiogenesis mediated by vascular endothelial growth factor (VEGF) is inhibited the recombinant humanized (rhu) monoclonal antibody (MAb) rhuMAbVEGF, which has synergy with chemotherapy in animal models. The present study was designed to assess safety and pharmacokinetics of weekly intravenous (IV) rhuMAbVEGF one three standard regimens. PATIENTS AND METHODS: Twelve adult patients were enrolled four on each combination. 3 mg/kg IV, administered for 8 weeks (1) doxorubicin 50 mg/m2 every 4 weeks; (2) carboplatin at area under curve 6 plus paclitaxel 175 (3) fluorouracil (5-FU) 500 leucovorin 20 weekly, 1 weeks. RESULTS: median number doses delivered eight (range, doses). Grade toxicities diarrhea (one 5-FU patient), thrombocytopenia (two paclitaxel), leukopenia patient p...
sci-hub.se 参考文章(24)
Jones A, Harris Al, New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. The cancer journal from Scientific American. ,vol. 4, pp. 209- 217 ,(1998)
M.A. Goldberg, T.J. Schneider, Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin Journal of Biological Chemistry. ,vol. 269, pp. 4355- 4359 ,(1994) , 10.1016/S0021-9258(17)41787-X
Robert S. Kerbel, A cancer therapy resistant to resistance Nature. ,vol. 390, pp. 335- 336 ,(1997) , 10.1038/36978
Thomas Boehm, Judah Folkman, Timothy Browder, Michael S. O'Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature. ,vol. 390, pp. 404- 407 ,(1997) , 10.1038/37126
Dieter Marmé, Karin Weindel, Georg Martiny-Baron, Bernhard Barleon, Katja Mohrs, Gerhard Siemeister, Reversion of Deregulated Expression of Vascular Endothelial Growth Factor in Human Renal Carcinoma Cells by von Hippel-Lindau Tumor Suppressor Protein Cancer Research. ,vol. 56, pp. 2299- 2301 ,(1996)
Unnur P. Thorgeirsson, Hitoshi Yoshiji, Steven R. Harris, Vascular Endothelial Growth Factor Is Essential for Initial but not Continued in Vivo Growth of Human Breast Carcinoma Cells Cancer Research. ,vol. 57, pp. 3924- 3928 ,(1997)
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
Napoleone Ferrara, Keith Houck, LYN Jakeman, David W Leung, None, Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins Endocrine Reviews. ,vol. 13, pp. 18- 32 ,(1992) , 10.1210/EDRV-13-1-18
Gabriele Bergers, Kashi Javaherian, Kin-Ming Lo, Judah Folkman, Douglas Hanahan, Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice Science. ,vol. 284, pp. 808- 812 ,(1999) , 10.1126/SCIENCE.284.5415.808